8-K: DT Cloud Star to Merge with PrimeGen US in $1.49B Deal

DT Cloud Star Acquisition Corporation has entered into a definitive business combination agreement to merge with PrimeGen US, Inc., a biotechnology company focused on stem cell therapies, valuing PrimeGen at approximately $1.49 billion.

Summary

• DT Cloud Star Acquisition Corporation (DTCS), a Cayman Islands exempted company, will merge with PrimeGen US, Inc., a Delaware corporation, through a two-step business combination.
• The transaction involves a Redomestication Merger where DTCS merges into DTSQ Purchaser Inc. (Purchaser), followed by an Acquisition Merger where DTSQ Merger Sub Inc. merges into PrimeGen US, Inc.
• PrimeGen US, Inc. will survive the Acquisition Merger as a wholly-owned subsidiary of Purchaser.
• The aggregate value of the merger consideration for PrimeGen stockholders is $1,489,800,000, to be paid in Purchaser Class A Common Stock, adjusted for outstanding Company Warrants and Stock Options.
• Purchaser will issue 1,931,900 Non-Redemption Warrants to public shareholders who do not redeem their Parent Ordinary Shares and other Parent Ordinary Share holders.
• These Non-Redemption Warrants will have an exercise price of $2.00 per share of Purchaser Class A Common Stock and will be exercisable starting six months after the Closing Date for a period of two years.
• Significant Company Holders, representing 87.40% of PrimeGen's capital stock, have agreed to vote in favor of the business combination.
• The Sponsor and Parent's directors and officers have also agreed not to transfer or redeem their shares and to vote in favor of the merger.
• A new equity incentive plan will be adopted, providing for awards equal to 15% of the aggregate number of Purchaser Common Stock shares issued and outstanding immediately after the Closing.
• The Sponsor will receive a $2,500,000 payment at closing in exchange for 250,000 shares of Purchaser Common Stock.
• The Company has an FDA reference number in connection with its pre-IND meeting and future IND application to test PGSXC-L1A cell therapy product candidate for Acute Alcoholic Hepatitis.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development. While the merger provides a clear path to public markets for PrimeGen, a biotech company with promising stem cell therapies, the lack of detailed financial performance and the low exercise price of non-redemption warrants introduce some uncertainty regarding the immediate post-merger valuation and potential dilution.

Positives

• PrimeGen US, Inc. is a biotechnology company focused on the research and development of life-saving stem cell therapies, indicating potential for high growth and significant medical impact.
• The company has an FDA reference number for a pre-IND meeting and future IND application for its PGSXC-L1A cell therapy product candidate for Acute Alcoholic Hepatitis, suggesting progress in its regulatory pathway.
• Strong internal support for the merger is evidenced by Significant Company Holders (representing 87.40% of PrimeGen's capital stock) and Parent's insiders agreeing to vote in favor and not redeem shares.
• The transaction provides a clear pathway for PrimeGen to become a publicly traded entity, potentially enabling access to broader capital markets for funding its research and development.
• A new equity incentive plan, representing 15% of post-closing Purchaser Common Stock, is designed to attract and retain key talent, aligning management and employee interests with shareholder value.

Negatives

• The filing is primarily a legal document outlining merger mechanics and agreements, lacking detailed current financial performance or projections for PrimeGen US, Inc., making a comprehensive financial assessment challenging.
• The stated merger consideration of $1,489,800,000 for PrimeGen is presented without context of current revenue, profitability, or market comparables within the filing, hindering an objective valuation assessment.
• The issuance of 1,931,900 Non-Redemption Warrants with a $2.00 exercise price to non-redeeming public shareholders may indicate concerns about high redemption rates, a common issue in SPAC transactions, and could lead to significant dilution.
• The Sponsor Closing Payment of $2,500,000 for 250,000 shares implies a $10.00 per share valuation for the Sponsor's shares, which contrasts sharply with the $2.00 exercise price of the Non-Redemption Warrants, raising questions about valuation consistency.

Risks

• The proposed Business Combination may not be completed in a timely manner or at all, which could adversely affect the price of DTCS's securities.
• Failure to satisfy the conditions to the consummation of the proposed Business Combination, including shareholder approvals and governmental/regulatory approvals.
• Redemptions by DTCS's public shareholders may exceed anticipated levels.
• The combined company may fail to meet Nasdaq initial listing standards.
• The proposed Business Combination could disrupt PrimeGen's current plans and operations and impact business relationships.
• The outcome of any legal proceedings related to the Business Combination Agreement or the proposed Business Combination could be unfavorable.
• Changes in the markets in which PrimeGen competes, including competitive landscape, technology evolution, or regulatory changes, could adversely affect the combined company.
• The combined company may be unable to execute its growth strategies.
• Risks related to supply chain disruptions.
• The combined company may not be able to develop and maintain effective internal controls.
• Costs related to the proposed Business Combination may be higher than anticipated, and anticipated benefits or pro forma results may not be realized.
• Inability to achieve successful results or obtain licensing of third-party intellectual property rights for future discovery and development of PrimeGen's projects.
• Failure to commercialize products and achieve market acceptance of such products.
• The combined company may need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all.
• Difficulties in managing growth and expanding operations post-combination.
• Risk of product liability or regulatory lawsuits or proceedings relating to PrimeGen's business.
• Risks associated with intellectual property protection, including the inability to secure or protect its intellectual property.

Future Outlook

The combined company, operating as PrimeGen US, Inc. under the Purchaser entity, intends to continue its focus on the research and development of life-saving stem cell therapies. Key future activities include advancing the PGSXC-L1A cell therapy product candidate for Acute Alcoholic Hepatitis through the regulatory process, following a pre-IND meeting with the FDA. The successful completion of the business combination is expected to provide the necessary capital and public market access to support these strategic objectives and growth initiatives.

Management Comments

• The boards of directors of Parent, Purchaser, Merger Sub, and the Company have each determined that the Mergers are fair, advisable, and in the best interests of their respective companies and stockholders.
• The Parent's board of directors has resolved to recommend that its shareholders approve the Business Combination Agreement and related transactions.
• The Company's board of directors has resolved to recommend that its stockholders vote in favor of the Business Combination Agreement and related transactions.

Industry Context

StockSavvy.ai notes that this SPAC merger provides a path for PrimeGen US, Inc., a biotechnology company specializing in stem cell therapies, to access public markets. The focus on 'life-saving stem cell therapies' positions PrimeGen in a high-growth, high-potential segment of the biotech industry, which often attracts significant investor interest due to its innovative nature and potential for substantial medical breakthroughs. The successful completion of such a merger could enable PrimeGen to accelerate its research and development efforts, particularly for product candidates like PGSXC-L1A for Acute Alcoholic Hepatitis, by leveraging public capital.

Comparison to Industry Standards

• The valuation of $1.4898 billion for PrimeGen US, Inc. is substantial for a pre-revenue or early-stage biotech company, suggesting high expectations for its stem cell therapy pipeline, particularly PGSXC-L1A. For comparison, other early-stage biotech companies with promising but unproven therapies often command valuations ranging from hundreds of millions to a few billion dollars, depending on the stage of clinical development, market potential, and intellectual property strength. For example, companies like Sana Biotechnology (focused on engineered cells) or Intellia Therapeutics (CRISPR gene editing) had multi-billion dollar valuations at similar stages, reflecting the high-risk, high-reward nature of the sector.
• The Non-Redemption Warrants with a $2.00 exercise price, compared to a typical SPAC IPO price of $10.00, are a common feature in SPAC deals facing high redemption rates, aiming to incentivize existing public shareholders to remain invested. This mechanism is similar to those seen in other SPAC mergers where shareholder redemptions were a concern, such as the merger between Lucid Motors and Churchill Capital Corp IV, where PIPE investors received warrants or discounted shares.
• The 15% equity incentive plan for post-closing Purchaser Common Stock is within the typical range (10-20%) for SPAC transactions, designed to align management and employee incentives with shareholder value creation in the combined entity.

Management Changes

Corporate Governance

Related Party Transactions

• Significant Company Holders (including PrimeGen Global, Inc., Stem Med Scientific Inc., Daniel Chiu, Wai Sun Szeto, Dora E. Chan Trust, Dora E. Chan, and Rita YuKa Wong) entered into a Company Support Agreement to vote in favor of the merger.
• The Sponsor (DT Cloud Star Management Limited) and Parent's directors and officers (Kenneth Lam, Jiayi Liang, Shaoke Li, Longjiao Li, Chi Zhang, Sam Zheng Sun, and Xunyong Zhou) entered into an Insider Support Agreement to vote in favor and not redeem shares.
• The Sponsor will receive a $2,500,000 payment at closing in exchange for 250,000 shares of Purchaser Common Stock.
• Parent Transaction Expenses, including any loans owed by Parent to the Sponsor, will be paid from the Trust Account and/or Closing PIPE proceeds.
• CTM Advisory Limited (Corporate Advisor) and A.G.P./Alliance Global Partners, LLC (Financial Advisor) will receive shares of Purchaser Class A Common Stock as compensation for their services in connection with the mergers.

Stakeholder Impact

• **DTCS Public Shareholders:** Will receive Purchaser Class A Common Stock and Non-Redemption Warrants if they do not redeem their shares, and their vote is required for the merger's approval.
• **PrimeGen Stockholders:** Will receive Purchaser Class A or Class B Common Stock as merger consideration and will be subject to lock-up agreements for a period post-closing.
• **Employees of PrimeGen:** Current officers and directors will continue in the Surviving Corporation, and a new equity incentive plan is designed to retain and incentivize them.
• **Sponsor and Insiders of DTCS:** Will receive Non-Redemption Warrants and are subject to lock-up agreements; the Sponsor will also receive a closing payment. They have committed to support the transaction by voting in favor and not redeeming shares.
• **Creditors:** Existing indebtedness of PrimeGen, such as the Revolving Line of Credit Loan with East West Bank, will transfer to the Surviving Corporation.

Next Steps

• Parent will prepare and file a Form S-4 registration statement (including a proxy statement and prospectus) with the SEC.
• Parent will solicit proxies from its shareholders for an extraordinary general meeting (Parent EGM) to approve the merger and related proposals.
• The Company will obtain the Required Company Stockholder Approval via written consent within ten (10) days following the effectiveness of the Registration Statement.
• Parent will respond to SEC comments and use commercially reasonable efforts to cause the Registration Statement to clear comments and become effective.
• Parent will distribute the Registration Statement to its shareholders and hold the Parent EGM.
• The Purchaser Class A Common Stock issued as merger consideration must be approved for listing on Nasdaq.
• The Redomestication Merger and Acquisition Merger will close at least one business day after the Redomestication Merger, no later than three business days after all conditions are satisfied or waived.
• The Purchaser will establish an audit committee consisting of at least three independent directors within 90 days of Nasdaq listing, with one designated as an audit committee financial expert.
• The Sponsor, certain Company stockholders, and Company directors and officers will deliver duly executed lock-up agreements.
• The Purchaser will enter into a registration rights agreement with certain Company stockholders and the Sponsor.

Key Dates

Keywords

SPAC, Business Combination, Merger, Biotechnology, Stem Cell Therapy, PrimeGen US, DT Cloud Star, Warrants, Nasdaq Listing, Corporate Governance, SEC Filing, PGSXC-L1A, Acute Alcoholic Hepatitis